SALL4 and myelodysplastic syndrome: A recent study demonstrated that the use of demethylating agents such as decitabine and azacytidine can induce the expression of the oncogene SALL4 in patients with myelodysplastic syndrome (MDS), warranting caution in the use of these drugs.